Vancouver, British Columbia — November 24, 2025 — Leads & Copy —
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) has announced expanded data from its CONNECT SCI Study, showcasing sustained and significant improvements in function, independence, and quality of life for individuals with chronic spinal cord injury (SCI).
The follow-up data, which includes blinded exit interviews conducted up to 364 days after the study period, confirmed durable and wide-ranging upper and lower-body improvements compared to the placebo group. Participant-reported outcomes highlighted substantial improvements in bladder control and reduced muscle spasticity.
The CONNECT SCI Study was a 16-week, placebo-controlled trial involving individuals with chronic SCI, averaging 3.5 years post-injury. Participants were administered daily subcutaneous NVG-291 or a placebo for 12 weeks, followed by a 4-week observation period.
Key findings from the study include:
- NVG-291 participants showed a 2.6-fold greater mean improvement in GRASSP Total Score compared to placebo at Week 16.
- Hand function improvements were durable, with NVG-291 participants experiencing a 3.7-fold greater mean improvement in GRASSP Quantitative Prehension compared to placebo at Week 16.
- Exit interviews revealed NVG-291 participants reported more consistent, durable, and wide-ranging functional gains, particularly in limb movement, compared to placebo.
- NVG-291 participants reported that functional improvements often directly enabled greater daily independence and activity.
- Seventy-five percent of NVG-291 participants reported “much” or “very much” improved overall symptoms compared to 33% on placebo.
- Sixty-seven percent of NVG-291 participants reported improved bladder control compared to 22% of placebo participants.
- Fifty-six percent of NVG-291 participants reported reduced muscle spasticity compared to 22% of placebo participants.
According to NervGen, statistically significant reduction of hyperactive reticulospinal signaling in upper and lower limbs (via startle MEP), together with previously reported increases in corticospinal signaling (via MEP), establish the biological basis for NVG-291’s clinical efficacy.
Adam Rogers, MD, Interim Chief Executive Officer at NervGen Pharma, stated that the data builds upon landmark topline results and represents a moment of real hope for the SCI community. He added that NVG-291 continues to demonstrate the ability to restore clinically meaningful function and drive dramatic improvements in daily independence and quality of life.
The company also completed a productive FDA Type C meeting in September, where the FDA confirmed that multiple regulatory pathways are available to support approval of NVG-291. NervGen anticipates an End-of-Phase 2 meeting in early 2026 to align further with the FDA on the development and registration pathway for NVG-291.
Videos documenting functional changes following NVG-291 treatment are available on NervGen’s website.
NervGen holds exclusive worldwide rights to NVG-291, a first- and potential best-in-class therapeutic peptide targeting nervous system repair. The company is dedicated to developing innovative therapies that enable the nervous system to repair itself in settings of neurotrauma and neurologic disease.
Huitt Tracey, Investors, htracey@nervgen.com, 604.537.2094
David Schull or Ignacio Guerrero-Ros, Ph.D., Media, Russo Partners, David.Schull@russopartnersllc.com, Ignacio.Guerrero-Ros@russopartnersllc.com, 858.717.2310
Bill Adams, Chief Financial Officer, info@nervgen.com, 778.731.1711
Source: NervGen Pharma Corp.
